Mark Egerton, CEO of Quotient Sciences has been featured in and article in Global Business Reports: "Keeping Up With Demands: CDMOs diversify their capabilities to meet their clients’ complex requirements."
"According to Mark Egerton of Quotient Sciences, pharmaceutical companies developing drugs to treat rare disorders have two options in terms of distribution. They can either invest substantially into producing large quantities of product with an extended shelf life or hold off until patients have already been recruited and then deliver the drug to this population in a near just-in-time fashion. The latter is often attractive when dealing with patient populations so small that the recruitment process for trials can be a long and unpredictable journey."